# Ozempic vs Mounjaro: Dosage, Uses and Side Effects

Source: https://pepvault.app/drugs/compare/ozempic-vs-mounjaro

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Brand-name drugs](https://pepvault.app/drugs) Ozempic vs Mounjaro

Brand against brand · semaglutide and tirzepatide

# Ozempic vs Mounjaro

From the two FDA labels, read Nov 18, 2026 [Published by PepVault](https://pepvault.app/guides/how-we-research)

Ozempic is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk; Mounjaro is tirzepatide, a GIP and GLP-1 receptor agonist, from Eli Lilly.

FDA approved Ozempic for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Mounjaro is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes.

## Label against label

Ozempic and Mounjaro, from their FDA labels and Drugs@FDA

| Compared | [Ozempic](https://pepvault.app/drugs/ozempic) | [Mounjaro](https://pepvault.app/drugs/mounjaro) |
| --- | --- | --- |
| Active ingredient | semaglutide | tirzepatide |
| Class | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Maker | Novo Nordisk | Eli Lilly |
| Approved for | Type 2 diabetes; heart and kidney risk in type 2 diabetes | Type 2 diabetes (adults and children 10 and up); heart risk |
| Forms | Multi-dose pen; Single-dose prefilled syringe; Tablet | Single-dose pen or vial; Multi-dose vial or KwikPen |
| How often | once a week or once a day | once a week |
| Starting dose | 0.25 mg a week (injection); 1.5 mg a day (tablets) | 2.5 mg a week |
| Top dose on the label | 2 mg a week (injection); 9 mg a day (tablets) | 15 mg a week |
| Most reported side effect | Nausea, 20.3% on 1 mg (placebo 6.1%) | Nausea, 18% on 15 mg (placebo 4%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2017 | 2022 |

Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.

## The two dosing schedules

This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.

### Ozempic injection, once a week

Ozempic’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.

### Ozempic tablets, once a day

Ozempic’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.

### Mounjaro, once a week

Mounjaro’s steps as the label lays them out, lowest to highest; each bar’s height is its dose against the top dose. A dashed bar is a step the label allows only if more is needed.

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=brand-vs-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## A missed dose, on each label

- [Ozempic](https://pepvault.app/drugs/ozempic): A missed weekly injection is taken as soon as possible within 5 days. Past 5 days, the label skips it and the next dose comes on the usual day.
- [Mounjaro](https://pepvault.app/drugs/mounjaro): A missed Mounjaro dose can still be given within 4 days (96 hours). After that it is skipped and the next one comes on the usual day.

## The trial evidence

- [Semaglutide vs Tirzepatide: the trial evidence, compound against compound](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Ozempic: the label in full](https://pepvault.app/drugs/ozempic)
- [Mounjaro: the label in full](https://pepvault.app/drugs/mounjaro)

## Questions

### What is the difference between Ozempic and Mounjaro?

Ozempic is semaglutide, a GLP-1 receptor agonist; Mounjaro is tirzepatide, a GIP and GLP-1 receptor agonist. Their labels approve them for different uses and set different schedules.

### What are Ozempic and Mounjaro approved for?

Ozempic is approved for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Mounjaro is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes.

### How often are Ozempic and Mounjaro taken?

Ozempic is taken once a week or once a day, as an injection or a tablet; Mounjaro once a week, as an injection.

### What are the dose ranges of Ozempic and Mounjaro?

On their labels, Ozempic runs 0.25 mg to 2 mg once a week or 1.5 mg to 9 mg once a day, and Mounjaro 2.5 mg to 15 mg once a week. A prescriber sets the actual dose.

### What is the most common side effect of Ozempic and Mounjaro?

On Ozempic’s label: nausea, 20.3% on 1 mg (placebo 6.1%). On Mounjaro’s: nausea, 18% on 15 mg (placebo 4%).

## Sources

- [OZEMPIC (semaglutide) injection, for subcutaneous use, FDA label on DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79) (version 20, published Jun 10, 2026; read Nov 18, 2026)
- [RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, for oral use, FDA label on DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98) (version 14, published Aug 19, 2026; read Nov 18, 2026)
- [MOUNJARO (tirzepatide) injection, for subcutaneous use, FDA label on DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0) (version 40, published Sep 2, 2026; read Nov 18, 2026)
- [Drugs@FDA, NDA 209637](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209637) (Ozempic, the injection; application first approved 2017)
- [Drugs@FDA, NDA 213051](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213051) (Ozempic, the tablets, added to the application by supplement 30 on Jan 30, 2026; application first approved 2019)
- [Drugs@FDA, NDA 215866](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866) (Mounjaro, the injection; application first approved 2022)

PepVault is not affiliated with Novo Nordisk. Ozempic is a trademark of its owner. PepVault is not affiliated with Eli Lilly. Mounjaro is a trademark of its owner.

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=brand-vs-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=brand-vs-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## On the two labels

### Read further

- [Semaglutide vs Tirzepatide: the trial evidence, compound against compound](https://pepvault.app/peptides/compare/semaglutide-vs-tirzepatide)
- [Ozempic: the label in full](https://pepvault.app/drugs/ozempic)
- [Mounjaro: the label in full](https://pepvault.app/drugs/mounjaro)

<!--promo-->

PepVault for iPhone

## Keep your own record in PepVault

Log each dose on your schedule, with a reminder for the next one.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=brand-vs-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Brand-name drugs

- [Every brand, by ingredient](https://pepvault.app/drugs)
- [Ozempic](https://pepvault.app/drugs/ozempic)
- [Mounjaro](https://pepvault.app/drugs/mounjaro)

## More pairs

- [Ozempic vs Wegovy](https://pepvault.app/drugs/compare/ozempic-vs-wegovy)
- [Ozempic vs Rybelsus](https://pepvault.app/drugs/compare/ozempic-vs-rybelsus)
- [Ozempic vs Zepbound](https://pepvault.app/drugs/compare/ozempic-vs-zepbound)
- [Ozempic vs Victoza](https://pepvault.app/drugs/compare/ozempic-vs-victoza)
- [Ozempic vs Trulicity](https://pepvault.app/drugs/compare/ozempic-vs-trulicity)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it. PepVault is not affiliated with Novo Nordisk. Ozempic is a trademark of its owner. PepVault is not affiliated with Eli Lilly. Mounjaro is a trademark of its owner.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
